biologic

Novolin N

insulin isophane human

Loss of exclusivityJuly 2003projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameNovolin N
Active ingredientinsulin isophane human
Strength1,000UNITS/10ML (100UNITS/ML)
Dosage formInjectable Suspension
RouteSubcutaneous
ModalityBiologic
FDA approvalJuly 1991
Marketing statusOTC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Novolin N patent cliff — loss of exclusivity July 2003 | CliffBio